Drug treatment strategies for paget’s disease: relieving pain and preventing progression

References

• Paget J. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans. 1876;60(1):37–63.
   Google Scholar
• Kanis JA. Pathophysiology and treatment of Paget’s disease of bone. 2nd edn ed. London: Martin Dunitz; 1992.
   Google Scholar
• Gennari L, Rendina D, Falchetti A, et al. Paget’s Disease of Bone. Calcif Tissue Int. 2019;104(5):483–500. DOI:10.1007/s00223-019-00522-3
   PubMed Web of Science ®Google Scholar
• Gennari L, Rendina D, Picchioni T, et al. Paget’s disease of bone: an update on epidemiology, pathogenesis and pharmacotherapy. Expert Opin Orphan Drug. 2018;6(8):485–496. DOI:10.1080/21678707.2018.1500691
   Web of Science ®Google Scholar
• Singer FR, Mills BG, Gruber HE, et al. Ultrastructure of bone cells in Paget’s disease of bone. J Bone Miner Res. 2006;21(2):51–54. DOI:10.1359/jbmr.06s209
   Google Scholar
• Reddy SV, Kurihara N, Menaa C, et al. Paget’s disease of bone: a disease of the osteoclast. Rev Endocr Metab Disord. 2001;2(2):195–201. DOI:10.1023/A:1010010912302
   PubMedGoogle Scholar
• Alvarez L, Guanabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res. 1995;10(3):458–465. DOI:10.1002/jbmr.5650100318
   PubMedGoogle Scholar
• Singer FR, Hg B 3rd, Hosking DJ, et al. Paget’s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408–4422. DOI:10.1210/jc.2014-2910.
   PubMedGoogle Scholar
• Al Nofal AA, Altayar O, BenKhadra K, et al. Bone turnover markers in Paget’s disease of the bone: a systematic review and meta-analysis. Osteoporos Int. 2015;26(7):1875–1891. DOI:10.1007/s00198-015-3095-0
   PubMedGoogle Scholar
• Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of paget’s disease of bone in adults: a clinical guideline. J Bone Miner Res. 2019;34(4):579–604. DOI:10.1002/jbmr.3873.
   PubMedGoogle Scholar
• Smith SE, Murphey MD, Motamedi K, et al. Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics. 2002;22(5):1191–1216. DOI:10.1148/radiographics.22.5.g02se281191
   PubMedGoogle Scholar
• Fogelman I, Carr D, Boyle IT. The role of bone scanning in Paget’s disease. Metab Bone Dis Relat Res. 1981;3(4–5):243–254.
   PubMedGoogle Scholar
• Fogelman I, Carr D. A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget’s disease. Eur J Nucl Med. 1980;5(5):417–421.
   PubMedGoogle Scholar
• Mangham DC, Davie MW, Grimer RJ. Sarcoma arising in Paget’s disease of bone: declining incidence and increasing age at presentation. Bone. 2009;44:431–436.
   PubMed Web of Science ®Google Scholar
• Rendina D, De Filippo G, Ralston SH, et al. Clinical characteristics and evolution of giant cell tumor occurring in Paget’s disease of bone. J Bone Miner Res. 2015;30(2):257–263.
   PubMedGoogle Scholar
• Kaplan FS. Surgical management of Paget’s disease. J Bone Miner Res. 1999;14(2):34–38.
   PubMedGoogle Scholar
• Tancioni F, Di Ieva A, Levi D, et al. Spinal decompression and vertebroplasty in Paget’s disease of the spine. Surg Neurol. 2006;66(2):189–191.
   PubMedGoogle Scholar
• Lewallen DG. Hip arthroplasty in patients with Paget’s disease. Clin Orthop Relat Res. 1999;369:243–250.
   Google Scholar
• Hernandez NM, Vakharia RM, Bolognesi MP, et al. Do patients with paget’s disease have worse outcomes following primary total knee arthroplasty? J Knee Surg. [2021 May 14]. Epub ahead of print. DOI:10.1055/s-0041-1727180
   Google Scholar
• Corral-Gudino L, Tan AJ, Del Pino-Montes J, et al. Bisphosphonates for Paget’s disease of bone in adults. Cochrane Database Syst Rev. 2017;12(12):CD004956.
   PubMedGoogle Scholar
• Siris ES, Feldman F. Natural history of untreated Paget’s disease of the tibia. J Bone Miner Res. 1997;12:691–692.
   PubMed Web of Science ®Google Scholar
• Dodd GW, Ibbertson HK, Fraser TR, et al. Radiological assessment of Paget’s disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol. 1987;60:849–860.
   PubMedGoogle Scholar
• Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am j med. 1996;101:341–348.
   PubMed Web of Science ®Google Scholar
• Gutteridge DH, Retallack RW, Ward LC, et al. Clinical, biochemical, hematologic, and radiographic responses in Paget’s disease following intravenous pamidronate disodium: a 2-year study. Bone. 1996;19:387–394.
   PubMedGoogle Scholar
• Brown JP, Chines AA, Myers WR, et al. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone. 2000;26:263–267.
   PubMedGoogle Scholar
• Peris P, Alvarez L, Vidal S, et al. Treatment with tiludronate has a similar effect to risedronate on Paget’s disease activity assessed by bone markers and bone scintigraphy. Clin Exp Rheumatol. 2007;25:206–210.
   PubMedGoogle Scholar
• Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab. 1996;81:961–967.
   PubMed Web of Science ®Google Scholar
• Bickerstaff DR, Douglas DL, Burke PH, et al. Improvement in facial deformity of Paget disease treated with diphosphonates. J Bone Joint Surg Br. 1990;72:132–136.
   PubMedGoogle Scholar
• Murdin LM, Yeoh LH. Hearing loss treated with pamidronate. J R Soc Med. 2005;98:272–274.
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Vignot E. Therapeutic strategy in Paget’s disease of bone. Bone. 1995;17:489S–491S.
   PubMed Web of Science ®Google Scholar
• Wallace E, Wong J, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med. 1995;155:1813–1815.
   PubMedGoogle Scholar
• Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res. 2010;25:20–31.
   PubMed Web of Science ®Google Scholar
• Tan A, Goodman K, Walker A, et al. Long-term randomized trial of intensive versus symptomatic management in Paget’s disease of bone: the PRISM-EZ study. J Bone Miner Res. 2017;32:1165–1173.
   PubMed Web of Science ®Google Scholar
• Cundy T, Maslowski K, Grey, A, et al. Durability of response to zoledronate treatment and competing mortality in Paget’s disease of bone. J Bone Miner Res. 2017;32:753–756.
   PubMed Web of Science ®Google Scholar
• Cundy T. Treating paget’s disease-why and how much? J Bone Miner Res. 2017;32(6):1163–1164.
   PubMedGoogle Scholar
• Lavender JP, Evans IM, Arnot R, et al. A comparison of radiography and radioisotope scanning in the detection of Paget’s disease and in the assessment of response to human calcitonin. Br J Radiol. 1977;50(592):243–250.
   PubMedGoogle Scholar
• Gennari C, Passeri M, Chierichetti SM, et al. Side-effects of synthetic salmon and human calcitonin. Lancet. 1983;1(8324):594–595.
   PubMedGoogle Scholar
• Pontiroli AE, Pajetta E, Calderara A, et al. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget’s disease of bones: a pilot study. J Endocrinol Invest. 1991;14(1):47–51.
   PubMedGoogle Scholar
• Ralston SH. Bisphosphonates in the management of Paget’s disease. Bone. 2020;138:115465.
   PubMedGoogle Scholar
• Russell G. Bisphosphonates from bench to bedside. Ann NY Acad Sci. 2006;1068:367–401.
   PubMed Web of Science ®Google Scholar
• Smith R, Russell RGG, Bishop M. Diphosphonates and Paget’s disease of bone. Lancet. 1971;1(7706):945–947.
   PubMedGoogle Scholar
• Delmas PD, Chapuy MC, Vignon E, et al. Long term effects of dichloromethylene diphosphonate in Paget’s disease of bone. J Clin Endocrinol Metab. 1982;54(4):837–844.
   PubMedGoogle Scholar
• Reginster JY, Colson F, Morlock G, et al. Evaluation of the efficacy and safety of oral tiludronate in Paget’s disease of bone. A double blind, multiple-dosage, placebo-controlled study. Arthritis & Rheumatism. 1992;35(8):967–974.
   PubMedGoogle Scholar
• Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget’s disease of bone. Arthritis & Rheumatism. 1995;38(6):851–858.
   PubMedGoogle Scholar
• Johnston CC, Khairi MR, Meunier PJ. Use of etidronate (EHDP) in Paget’s disease of bone. Arthritis & Rheumatism. 1980;23(10):1172–1176.
   PubMedGoogle Scholar
• Boyce BF, Smith L, Fogelman I, et al. Focal osteomalacia due to low-dose diphosphonate therapy in Paget’s disease. Lancet. 1984;1(8381):821–824.
   PubMedGoogle Scholar
• Diez-Perez A. Bisphosphonates. Maturitas. 2002;43(1):S19–26.
   PubMedGoogle Scholar
• Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;11:196–214.
   Google Scholar
• O’doherty DP, Gertz BJ, Tindale W, et al. Effects of five daily 1 h infusions of alendronate in Paget’s disease of bone. J Bone Miner Res. 1992;7:81–87.
   PubMed Web of Science ®Google Scholar
• Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget’s disease of bone. Bone. 1994;15(4):415–417.
   PubMed Web of Science ®Google Scholar
• Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of bone. Bone. 2004;34(4):747–754.
   PubMedGoogle Scholar
• Brown JP, Hosking DJ, Ste-Marie L, et al. Risedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose-response study. Calcif Tissue Int. 1999;64(2):93–99.
   PubMed Web of Science ®Google Scholar
• Hosking DJ, Eusebio RA, Chines AA. Paget’s disease of bone: reduction of disease activity with oral risedronate. Bone. 1998;22(1):51–55.
   PubMedGoogle Scholar
• Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res. 1998;13(6):1032–1038.
   PubMed Web of Science ®Google Scholar
• Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone. paget’s risedronate/etidronate study group. Am j med. 1999;106(5):513–520.
   PubMedGoogle Scholar
• Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med. 2005;353(9):898–908.
   PubMed Web of Science ®Google Scholar
• Reid IR, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res. 2011;26(9):2261–2270.
   PubMedGoogle Scholar
• Frijlink WB, Bijvoet OL, Te Velde J, et al. Treatment of Paget’s disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979;1(8120):799–803.
   PubMedGoogle Scholar
• Harinck HIJ, Papapoulos SE, Blanksma HJ, et al. Paget’s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J. 1987;295:1301–1305.
   PubMedGoogle Scholar
• Gennari L, Merlotti D, Mossetti G, et al. The use of intravenous aminobisphosphonates for the treatment of Paget’s disease of bone. Mini Rev Med Chem. 2009;9(9):1052–1063.
   PubMedGoogle Scholar
• Gallacher SJ, Boyce BF, Patel U, et al. Clinical experience with pamidronate in the treatment of Paget disease of bone. Ann Rheum Dis. 1991;50:930–933.
   PubMedGoogle Scholar
• Cundy T, Wattie D, King AR. High-dose pamidronate in the management of resistant Paget disease. Calcif Tissue Int. 1996;58:6–8.
   PubMedGoogle Scholar
• Trombetti A, Arlot M, Thevenon J, et al. Effect of multiple intravenous pamidronate courses in Paget disease of bone. Rev Rhum (Engl Ed). 1999;66:467–476.
   PubMedGoogle Scholar
• Adamson BB, Gallacher SJ, Byars J, et al. Mineralization defects with pamidronate therapy for Paget disease. Lancet. 1993;342:1459–1460.
   PubMedGoogle Scholar
• Boyce BF, Adamson BB, Gallacher SJ, et al. Mineralization defects after pamidronate for Paget disease. Lancet. 1994;343:1231–1232.
   PubMed Web of Science ®Google Scholar
• Merlotti D, Gennari L, Martini G, et al. Comparison of different intravenous bisphosphonate regimens for Paget’s disease of bone. J Bone Miner Res. 2007;22(10):1510–1517.
   PubMedGoogle Scholar
• Arden-Cordone M, Siris ES, Lyles KW, et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget disease of bone. Calcif Tissue Int. 1997;60:415–418.
   PubMed Web of Science ®Google Scholar
• Buckler H, Fraser W, Hosking D, et al. Single infusion of zoledronate in Paget disease of bone: a placebo controlled, dose-ranging study. Bone. 1999;24:81S–85S.
   PubMed Web of Science ®Google Scholar
• Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22(1):142–148.
   PubMedGoogle Scholar
• Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone. 2004;35(1):224–230.
   PubMedGoogle Scholar
• Reid IR, Wattie D, Gamble GD, et al. Long-term effects of intravenous ibandronate in paget’s disease of bone. Calcif Tissue Int. 2017;100:250–254.
   PubMed Web of Science ®Google Scholar
• Atkins RM, Yates AJ, Gray RE, et al. Aminohexane disphosphonate in the treatment of Paget disease of bone. J Bone Miner Res. 1987;2:273–279.
   PubMedGoogle Scholar
• Delmas P, Chapuy MC, Edouard C, et al. Beneficial effects of aminohexane bisphosphonate in patients with Paget disease of bone resistant to sodium etidronate. Am j med. 1987;83:276–282.
   PubMedGoogle Scholar
• McCloskey EV, Yates AJP, Beneton MNC, et al. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone. 1987;8:S35–41.
   PubMedGoogle Scholar
• Coulton LA, Preston CJ, Couch M, et al. An evaluation of serum osteocalcin in Paget disease of bone and its response to diphosphonate treatment. Arthrit Rheum. 1988;31:1142–1147.
   PubMed Web of Science ®Google Scholar
• Filipponi P, Cristallini S, Policani G, et al. Paget disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone. 1998;23:543–548.
   PubMed Web of Science ®Google Scholar
• Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with Neridronate in Paget disease. Clin Exp Rheumatol. 2002;20:55–58.
   PubMed Web of Science ®Google Scholar
• Merlotti D, Rendina D, Gennari L, et al. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone. J Bone Miner Res. 2011;26:512–518.
   PubMed Web of Science ®Google Scholar
• Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41(6):326–331.
   PubMed Web of Science ®Google Scholar
• Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380–4387.
   PubMed Web of Science ®Google Scholar
• Merlotti D, Rendina D, Muscariello R, et al. Preventive role of vitamin D supplementation for acute phase reaction after bisphosphonate infusion in paget’s disease. J Clin Endocrinol Metab. 2020;105(3):dgz138.
   PubMedGoogle Scholar
• Bertoldo F, Pancheri S, Zenari S, et al. Serum 25-hydroxyvitamin D levels modulate the acute phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res. 2010;25(3):447–454.
   PubMedGoogle Scholar
• Gennari L, Rotatori S, Bianciardi S, et al. Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother. 2016;17(8):1141–1152.
   PubMed Web of Science ®Google Scholar
• Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399(10329):1080–1092.
   PubMed Web of Science ®Google Scholar
• Merlotti D, Gennari L, Martini G, et al. Current options for the treatment of Paget’s disease of the bone. Open Access Rheumatol. 2009;1:107–120.
   PubMedGoogle Scholar
• Reid IR, Sharma S, Kalluru R, et al. Treatment of paget’s disease of bone with denosumab: case report and literature review. Calcif Tissue Int. 2016;99(3):322–325.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Slavin J, McLachlan SA, et al. Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget’s disease: a case report. Oncol Lett. 2017;13(4):2105–2108.
   PubMedGoogle Scholar
• Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab. 2009;27(6):635–642.
   PubMed Web of Science ®Google Scholar
• de Roij van Zuijdewijn C, van Dorp W, Florquin S, et al. Bisphosphonate nephropathy: a case series and review of the literature. Br J Clin Pharmacol. 2021;87(9):3485–3491.
   PubMedGoogle Scholar
• Cronin O, Forsyth L, Goodman K, et al. Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone. BMJ Open. 2019;9(9):e030689.
   PubMedGoogle Scholar
• Cronin O, Subedi D, Forsyth L, et al. Characteristics of early paget’s disease in SQSTM1 mutation carriers: baseline analysis of the ZIPP study cohort. J Bone Miner Res. 2020;35:1246–1252.
   PubMedGoogle Scholar
• Gennari L, Rendina D, Merlotti D, et al. Update on the pathogenesis and genetics of Paget’s disease of bone. Front Cell Dev Biol. 2022;10:932065.
   PubMedGoogle Scholar
• Merlotti D, Materozzi M, Bianciardi S, et al. Mutation of PFN1 gene in an early onset, polyostotic paget-like disease. J Clin Endocrinol Metab. 2020;105(8):dgaa252.
   PubMedGoogle Scholar
• Gianfrancesco F, Rendina D, Merlotti D, et al. Giant cell tumor occurring in familial Paget’s disease of bone: report of clinical characteristics and linkage analysis of a large pedigree. J Bone Miner Res. 2013;28(2):341–350.
   PubMedGoogle Scholar
• Visconti MR, Langston AL, Alonso N, et al. Mutations of SQSTM1 are associated with severity and clinical outcome in Paget disease of bone. J Bone Miner Res. 2010 Nov;25(11):2368–2373.
   PubMed Web of Science ®Google Scholar
• Rendina D, De Filippo G, Merlotti D, et al. Vitamin D status in paget disease of bone and efficacy-safety profile of cholecalciferol treatment in pagetic patients with hypovitaminosis D. Calcif Tissue Int. 2019;105(4):412–422.
   PubMedGoogle Scholar
• Nagant Deuxchaisnes C D, Maldague B, Malghem J, et al. The action of the main therapeutic regimens on Paget’s disease of bone, with a note on the effect of vitamin D deficiency. Arthritis Rheum. 1980;23:1215–1234.
   Google Scholar